Blogs – Accident and Injury Experts

The chart is the case. Not the pain, not the sincerity, not how obviously the collision hurt you. The chart.

Everything that happens later — the adjuster’s evaluation, the examination the insurer arranges, the expert report, and, if it goes that far, the judge deciding whether an opinion is admissible — is downstream of what a physician wrote at the time and whether it can be checked.

Who actually reads it

Four readers, none of whom were in the room.

An adjuster, who scores the file against a schedule rather than reading it as a story. How that scoring works. An examining physician retained by the insurer, whose report will be shaped by what your record made easy or hard to say. What that examination is and how to prepare. A defense expert, whose job is to find the seam. And sometimes a court, applying a reliability standard to the opinion built on top of all of it. What Daubert requires of that opinion.

Write for those four, and the record also happens to be excellent medicine, because everything on the list below is something a treating physician should want to know anyway.

The seven elements

1. Mechanism and timeline. What happened, in what direction, with what forces, and when the symptoms began relative to it. Recorded early. Reconstructed six months later, it is testimony; recorded on day three, it is a contemporaneous medical record.
2. Diagnosis and the test that established it. Not “low back pain.” The structure, and what identified it — imaging read against the examination, electrodiagnostic testing, or a diagnostic block with a documented response.
3. Conservative care tried, with dates and outcomes. Most guideline indications for orthobiologics are explicitly conditioned on prior treatment having failed. A chart that cannot show what failed cannot establish the indication.
4. The indication mapped to a named guideline scenario. Not a general assertion that biologics help. The specific document, the specific target, and the specific evidence level it carries there.
5. Product characterization and guidance modality. What was in the syringe, in numbers, and how it was placed. Why this is the difference between a treatment and a charge.
6. Validated outcome measures, before and at intervals. Function, range, strength, a scored instrument — repeated on a schedule. A single glowing note at six weeks proves less than three ordinary measurements across six months.
7. Everything else in the plan. The rehabilitation, the loading program, the metabolic and behavioral work. Guidelines direct that these treatments be used alongside structured exercise and lifestyle management; a record showing the injection alone documents half a plan.

The three ways a biologic line item comes apart

Nothing in front of it. An injection appears in the record with no diagnostic work establishing the target. Every guideline in this field sequences diagnosis first, so the reviewer is not required to be hostile to reduce it — they only have to read.

Nothing behind it. The procedure is documented; the result is not. If no measurement was taken after, the treatment cannot be shown to have helped, and a treatment that cannot be shown to have helped is where the argument about reasonable value gets won by the other side.

Nothing describing it. The chart says PRP, right knee. That describes a category, not a treatment, and the reporting standards the profession publishes exist precisely because it does not.

What patients control

More than they think, and none of it requires medical training.

Keep your own timeline. Dates, symptoms, what you could not do that week, appointments attended. Contemporaneous beats reconstructed every time.

Do not leave gaps in treatment. A gap is scored as recovery whether or not that is what happened. If you have to stop, say why, and have the reason recorded.

Report function, not adjectives. “I cannot lift my daughter” is data. “It is pretty bad” is not. The record needs the first kind. How functional capacity gets formally measured.

Report everything, including what seems unrelated. Sleep, mood, concentration and the things that quietly disappear after an injury belong in the record, and they are routinely omitted because they feel like complaining. The half of the injury that is never photographed.

Ask which guideline. Ask your physician which published document supports the treatment being recommended, and write down the answer. A physician practicing inside a standard will tell you in one sentence.

What an opinion has to rest on

A causation opinion is only as strong as the record it is built on, which is why the record is built first and the opinion second. Every element above exists because someone will eventually ask how a conclusion was reached, and the answer has to be something other than clinical impression.

That is also why guideline-anchored treatment matters beyond the medicine. When care is delivered inside a written standard and documented against it, disagreement moves from the credibility of the patient to the content of the literature — and the literature, unlike a plaintiff, does not get rattled on cross-examination.

Frequently asked questions

What makes an orthobiologic treatment defensible in an injury claim?

A diagnosis established by a test, documented failure of prior conservative care, an indication mapped to a named guideline scenario, the product characterized in numbers, the guidance modality recorded, and validated outcome measures before and after. Learn more: the guideline record those indications map onto.

Why do gaps in treatment hurt a claim?

Because a gap is read as recovery. Claim evaluation is largely pattern-matching against a schedule, and an unexplained interval in the treatment record is scored as an interval in which the person was well. If you must pause care, have the reason documented at the time. Learn more: how injury claims are scored.

What should I tell my doctor that I might otherwise leave out?

Sleep, mood, concentration, what you have stopped doing, and anything that feels like complaining. Those are the consequences most often missing from a record and most often relevant to both treatment and valuation. Learn more: the secondary effects of injury.

Will an insurance examiner see my whole file?

Assume yes. An examination arranged by the insurer is conducted with your records in hand, and the report is shaped by what those records make easy or hard to conclude. Preparation matters, and so does the consistency of what is already written. Learn more: how these examinations actually work.

Does a strong record protect me from being called a malingerer?

It changes the terrain of that argument. Objective measurements repeated over time — function, imaging, electrodiagnostics, inflammatory markers — answer an accusation that subjective reports cannot. Learn more: what objective evidence answers.

Where is Injury Experts located?

Injury Experts is at 4477 Woodson Rd, Suite 202, St. Louis, MO 63134, next to Lambert International Airport, serving the St. Louis region in Missouri and Illinois. Call (314) 887-5866 or text (314) 886-5902.

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP — Board Certified in Anesthesiology, Pain Medicine, Interventional Pain Management, Addiction Medicine, and Obesity Medicine.

This article is for general education and is not medical advice. It does not create a physician–patient relationship. Do not start, stop, or change any medication — including opioid medication — without consulting your physician.

Two patients get “a PRP injection” for the same diagnosis, in the same year, in the same city. One improves. One does not, and concludes the treatment does not work.

They did not receive the same treatment. They may not have received it in the same anatomical structure.

How often a blind injection lands somewhere else

The accuracy of an unguided injection is worse than most people assume, and it has been measured.

At the hip, a systematic review and meta-analysis found ultrasound-guided injections accurate in 100% of cases against 72% for landmark-guided placement. At the shoulder girdle, another meta-analysis found accuracy of 93.6% versus 68.2% at the acromioclavicular joint, 92.5% versus 72.5% at the glenohumeral joint, and — the number worth sitting with — 86.7% versus 26.7% for the biceps tendon sheath.

The same review is honest about where guidance did not change accuracy: for the subacromial space, guided and unguided placement were comparable. Guidance is not a talisman. It matters most where the target is small, deep, or next to something that must not be injected.

Now apply that to a study. If a trial injects a joint blind and a quarter of the injections miss, the trial is not measuring the treatment. It is measuring the treatment diluted by a delivery failure rate — and that result then gets quoted back at patients as evidence that biologics do not work.

“PRP” is not a description of anything

Written on a bill, PRP is roughly as informative as writing “medication.” The orthopaedic profession has known this for years, which is why it published a minimum reporting standard for studies of biologics — covering platelet dose, leukocyte content, activation, volume, and how the preparation was produced.

Adherence to it is poor. A 2024 systematic review of 25 randomized trials in knee osteoarthritis, covering 2,356 patients, found the trials reported on average 53.1% of the checklist items. Not one reached 80%. The worst-reported category was activation, at 14%.

Those variables are not bookkeeping. A meta-analysis of randomized trials found the clinical effect in knee osteoarthritis influenced by the platelet concentration actually delivered. A meta-analysis of 18 level-1 studies found leukocyte-poor preparations producing better subjective knee scores than leukocyte-rich ones. Two clinics can both say PRP, use materially different products, and get materially different results.

What goes in the record for every injection here

1. The diagnosis, and the test that established it — imaging, electrodiagnostics, or a diagnostic block.
2. The anatomical target, named specifically rather than regionally.
3. The guidance modality used, ultrasound or fluoroscopy, with images retained.
4. The preparation: system used, volume, platelet concentration, leukocyte content, whether activated.
5. The published guidance or consensus scenario the indication maps onto.
6. A validated outcome measure before, and at intervals after.
7. What was done alongside it — loading program, rehabilitation, metabolic care.

Seven lines. They are the difference between a treatment that can be evaluated and a charge that can only be disputed. Why that record is written for a reader you have not met.

When the tendon needs debriding, not filling

Not every damaged structure wants an injection. Chronically degenerated tendon tissue is not inflamed tissue waiting for a signal; it is disorganized tissue occupying space where organized tissue should be.

Percutaneous hydro-resection [ultrasound-guided removal of degenerated tendon tissue] addresses that directly. A fine saline jet, placed under real-time ultrasound, is used to break up and remove diseased tissue while leaving healthy tendon intact, through an opening that needs no stitches. It is a structural correction rather than a biological signal, and choosing between the two is a diagnostic decision, not a preference.

The general principle holds across everything on this page: match the tool to what the tissue is actually doing. An injection into disorganized tissue and a debridement of an inflamed joint are both precise procedures aimed at the wrong problem.

What to ask before you let anyone inject you

What is the target, and what proved it. Under what imaging. What exactly is in the syringe, in numbers. And what measurement will tell us in three months whether this worked. A clinic that answers those four in a sentence each is practicing precisely. A clinic that finds the questions unusual is telling you something.

Frequently asked questions

Does ultrasound guidance really change an injection result?

It changes accuracy, substantially, at targets where accuracy is hard. Meta-analyses found ultrasound guidance accurate in 100% of hip injections versus 72% landmark-guided, and 86.7% versus 26.7% for the biceps tendon sheath — while finding no accuracy difference at the subacromial space. Learn more: how image-guided procedures fit into a treatment plan.

What should the record say about what was injected?

System used, volume, platelet concentration, leukocyte content, and whether the preparation was activated — the variables in the orthopaedic profession’s minimum reporting standard. A 2024 review found randomized trials reported barely half of those items on average, which is why results vary between clinics using the same word. Learn more: what a defensible treatment record contains.

Is leukocyte-rich or leukocyte-poor PRP better?

For knee osteoarthritis, a meta-analysis of 18 level-1 studies found leukocyte-poor preparations produced better subjective knee scores. The relevant point for a patient is that the two are different products, and the difference should appear in your chart. Learn more: what the knee evidence actually shows.

What is percutaneous hydro-resection?

Ultrasound-guided removal of degenerated tendon tissue using a fine saline jet, which breaks up and removes diseased tissue while leaving healthy tendon intact. It treats a structural problem rather than delivering a biological signal, and the choice between them is diagnostic. Learn more: how procedures are selected against the diagnosis.

Why do some studies find PRP ineffective?

Several reasons that are not about the biology: the indication studied, the preparation used, the concentration delivered, and whether the needle reached the target. Blind injections miss often enough to dilute a result, and trials frequently do not report the preparation in enough detail to compare. It is also genuinely negative for some indications. Learn more: where the evidence is positive and where it is not.

Where is Injury Experts located?

Injury Experts is at 4477 Woodson Rd, Suite 202, St. Louis, MO 63134, next to Lambert International Airport, serving the St. Louis region in Missouri and Illinois. Call (314) 887-5866 or text (314) 886-5902.

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP — Board Certified in Anesthesiology, Pain Medicine, Interventional Pain Management, Addiction Medicine, and Obesity Medicine.

This article is for general education and is not medical advice. It does not create a physician–patient relationship. Do not start, stop, or change any medication — including opioid medication — without consulting your physician.

Autologous is a quiet word doing enormous work. It means the injectate is manufactured from the patient — their blood, their marrow, their platelets, their growth factors. There is no supplier, no batch number, no quality control department. The raw material is whatever biology walked into the room.

Which makes the obvious question the one nobody asks before the appointment: what condition is the raw material in?

The confession that belongs at the front of this

Dr. Padda spent the first two decades of his career telling patients with a creeping A1C that it was not too bad, because that is what he had been taught to say. He was wrong, and he says so publicly, because the physiology he learned later changed how he treats pain rather than merely how he counsels about diet. Nobody gets to be the authority on metabolic disease without first admitting they misread it for twenty years.

What the tissue is actually being asked to do

A platelet concentrate delivers a payload of growth factors into a specific place and asks the local tissue to mount a repair response. Whether that response happens depends on the environment it lands in — locally, and systemically.

Two upstream drivers matter most here. The first is metabolic inflammation: a chronic, low-grade inflammatory state that keeps the body in a breakdown-dominant posture rather than a repair-dominant one. The second is insulin resistance and the hyperinsulinemia that accompanies it, which alters how tissue handles fuel and how blood vessels behave in the smallest arteries that supply tendon and cartilage.

Then the third factor, which is not biological at all. It is the shift schedule, the second job, the four hours of sleep, the food available on the way home at eleven at night, and — after an injury — the financial pressure of a claim that will not resolve. Those are not soft variables. Sleep restriction and chronic stress are among the most reliable ways to raise inflammatory markers in a human being, and they are the variables a clinic never asks about. The longer version of that argument.

What the evidence supports, and what it does not

State this carefully, because it is where enthusiasm outruns data.

Metabolic disease is firmly associated with the tendon conditions people get injected for. A meta-analysis of risk factors for rotator cuff tendinopathy found diabetes associated with roughly a doubling of the odds — an odds ratio of 2.24 — and age over 50 with an odds ratio of 3.31. That is about who develops the condition, not about who responds to treatment for it, and the distinction matters.

On response, the honest finding runs partly against the intuition. A secondary analysis of a randomized trial that compared PRP with microfragmented adipose tissue in knee osteoarthritis found body mass index inversely correlated with quality-of-life and daily-activity outcomes in the adipose group — and not in the PRP group. Forty-nine patients completed twelve months. It is one trial, and body mass index is a crude proxy for metabolic health rather than a measurement of it. But no one should tell you that trial data prove a metabolic workup improves your PRP result. It does not exist yet.

What the guidance documents do say is that the response depends on patient selection and on preparation quality, and that the field’s own reporting is too inconsistent to isolate variables like this. That is an argument for measuring more, not for measuring less.

So why measure it at all

Three reasons that do not depend on a trial that has not been run.

First, because the terrain is a separate disease and it does not politely wait outside. Someone with untreated insulin resistance who gets an excellent knee injection still has untreated insulin resistance, and it will decide things about the next twenty years that the knee will not.

Second, because it is the most common explanation for the patient who did everything right and stayed in pain. When appropriate structural treatment has been delivered accurately and the pain persists, the environment is the remaining variable worth interrogating.

Third, because it is objective. An injured person spends months being told their pain is subjective. High- sensitivity CRP, markers of insulin resistance, lipid particle measures and A1C are numbers on a page with dates attached, and numbers with dates behave differently in a claim file than adjectives do. Why objective data is the answer to that accusation.

What gets measured

A metabolic and inflammatory panel as the starting point: high-sensitivity CRP, markers of insulin resistance, lipid particle measures, A1C — read alongside sleep, nicotine exposure, medication list and the clinical examination. No single value decides anything. The pattern does.

What gets asked of the patient, and why it works

Every recommendation here carries a physiological reason, or it does not get made.

Load the tissue. Tendon and cartilage adapt to mechanical demand; unloaded tissue does not remodel usefully, and immobilization after an injury is one of the most common self-inflicted causes of a bad outcome. Progressive loading is the stimulus the injection is supposed to make tolerable.

Sleep, seriously. Insufficient restorative sleep is associated with higher cortisol and higher inflammatory markers, and a cortisol-dominant state favors breakdown over repair. This is the single most commonly ignored input after an injury, largely because pain wrecks sleep and nobody treats the sleep.

Nicotine. It constricts the small vessels that supply the tissue you are trying to heal. If only one change is going to happen this month, that is the one.

Change what the background inflammation is fed. Acellular carbohydrates and industrial seed oils are not a moral question; they are an input to the inflammatory state that the injectate has to work inside.

None of this is aftercare. Roughly half of the treatment plan in this practice is behavioral, and it is the half that decides whether the interventional half holds.

What this has to do with the claim

Two things, one helpful and one not.

The unhelpful one first: a documented metabolic condition is exactly the alternative explanation a defense expert reaches for. If your knee hurts and your A1C is 6.9, someone will argue the arthritis was metabolic and the collision incidental.

The helpful one: the counter-argument only exists if the terrain was measured and addressed. A record showing inflammatory and metabolic markers tracked over time, with a treatment plan aimed at them, converts the defense’s alternative explanation into a documented comorbidity that was identified and managed — which is a different conversation entirely. How causation gets argued when a pre-existing condition is in the file.

Frequently asked questions

Does having diabetes mean an orthobiologic injection will not work?

No. What the evidence shows is that metabolic disease is associated with developing tendon problems in the first place — a meta-analysis found diabetes roughly doubled the odds of rotator cuff tendinopathy — not that it predicts failure of treatment. It is a reason to treat both, not a reason to withhold either. Learn more: why the biological terrain governs recovery.

Is there proof that fixing my metabolic markers improves PRP results?

Not from a trial designed to answer that question. One randomized-trial analysis found body mass index correlated with outcomes after microfragmented adipose tissue but not after PRP. Metabolic care is done because the metabolic disease is real and treatable in its own right, and because it is the most common explanation for pain that persists after accurate structural treatment. Learn more: what the guidelines do and do not establish.

What tests are involved?

A metabolic and inflammatory panel is the starting point: high-sensitivity CRP, markers of insulin resistance, lipid particle measures and A1C, interpreted alongside sleep, nicotine exposure, medications and the clinical examination. No single value is decisive. Learn more: how the panel is read.

Is this saying my injury pain is my own fault?

No. Metabolic inflammation is a physiological state that occurs in people of every build, and it is driven as much by sleep, shift work, stress and the food environment as by anything a person chooses. It changes how tissue heals. It says nothing about blame. Learn more: the consequences of injury that never make it into the record.

Could the insurance company use my metabolic condition against me?

They can try, and the answer is documentation rather than concealment. A record that identifies the condition, tracks its markers over time and treats it turns an alternative explanation into a managed comorbidity. Learn more: how causation is argued when a pre-existing condition is in the file.

Where is Injury Experts located?

Injury Experts is at 4477 Woodson Rd, Suite 202, St. Louis, MO 63134, next to Lambert International Airport, serving the St. Louis region in Missouri and Illinois. Call (314) 887-5866 or text (314) 886-5902.

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP — Board Certified in Anesthesiology, Pain Medicine, Interventional Pain Management, Addiction Medicine, and Obesity Medicine.

This article is for general education and is not medical advice. It does not create a physician–patient relationship. Do not start, stop, or change any medication — including opioid medication — without consulting your physician.

In 2025 the American Society of Interventional Pain Physicians published 119 pages on regenerative therapies for chronic low back pain. Thirty-five authors, thirty-three of them in the formal consensus, GRADE methodology, nineteen recommendations, and every single recommendation carried at 100% agreement.

Almost nobody in a claim file has read it. It is, nevertheless, the document that governs how this treatment is supposed to be used in the lumbar spine, and it is unusually blunt about its own limits.

The grades, target by target

The guideline does not grade “regenerative medicine.” It grades each anatomical target separately, because the evidence behind each one is different:

• Intradiscal PRP — Evidence Level III, Fair. Consensus recommendation: Moderate.
• Intradiscal bone marrow aspirate concentrate — Level III, Fair. Moderate.
• Epidural PRP — Level III, Fair. Moderate.
• Facet joint PRP and mesenchymal stem cells — Level IV, Limited. Moderate.
• Sacroiliac joint PRP — Level IV, Limited. Low.
• Functional spinal unit injections — Evidence Level Very Low. Low.

In plain language: for the disc and the epidural space, the supporting studies are mostly controlled but not top-tier, the panel reached moderate agreement that the treatment has a defined role, and the recommendation is for selected patients rather than for everyone with a sore back. For the sacroiliac joint the evidence is thinner and the recommendation is correspondingly weaker. Nobody claiming a sacroiliac indication gets to borrow the disc’s grade, and nobody treating a disc gets to borrow the knee literature.

What the guideline says besides the grades

Three things, and they are the parts a clinic selling injections would rather not print.

Diagnosis comes first. The guideline stipulates that regenerative therapy follows a thorough diagnostic evaluation. Low back pain is not a diagnosis; it is a location. The disc, the facet joints, the sacroiliac joint and the nerve root all produce pain that overlaps on the pain drawing and diverges completely on treatment. What a diagnostic block proves, and what it disproves.

It is not a monotherapy. The guideline directs that these treatments be used in conjunction with structured exercise, physical therapy and lifestyle management. An injection with no rehabilitation behind it is half a treatment plan being billed as a whole one.

It tells clinicians to talk about money before treatment. The precautions section instructs physicians to inform patients that these costs are mostly not covered by commercial insurance. The society writing the guideline and the insurer denying the claim agree completely about payment and disagree completely about evidence. Why those are two separate questions.

The limitation the guideline puts in its own text

The same document states that regenerative medicine remains in early stages of clinical validation, asks for careful optimism, and names the scarcity of high-quality studies as its central limitation.

Both things are true simultaneously, and any page that gives you only one half is selling something. A specialty society producing 119 pages, nineteen unanimous recommendations and a GRADE appraisal is evidence that this is established clinical practice with defined indications. It is not a declaration that the question is closed. Cite the levels; skip the adjectives.

Why the target matters more than the product

Patients arrive asking for PRP. That is the wrong unit of decision. The useful question is which structure is generating the signal, because that determines both the treatment and how much evidence stands behind it.

A herniated disc pressing a nerve root produces pain that is substantially chemical rather than purely mechanical, which is why an epidural intervention aimed at that inflammatory cascade can help when nothing has changed on the film. A facet-mediated pain pattern behaves differently and is confirmed differently. A sacroiliac joint is confirmed differently again. Each of those roads leads to a different grade in the table above. The middle ground between failed conservative care and major surgery.

Where a collision complicates the picture

The ASIPP guideline addresses chronic low back pain. A back injured six weeks ago is a different clinical situation, and the honest answer is that the acute phase is not where these graded recommendations were developed. Early care after an injury is about establishing the diagnosis, documenting the mechanism and the deficit, and restoring load tolerance — not about reaching for the most advanced thing available in week two.

The sequencing question also decides whether treatment survives review later. Care that follows the published order — diagnosis, conservative treatment, targeted intervention, biologic where indicated — reads as a treatment plan. Care that starts at the end reads as a product being sold, and it is valued that way by the person reviewing the file. How that review actually works.

What to take from a 119-page document

That the grades are specific, the sequence is mandatory, the payment conversation belongs before treatment rather than after it, and the society’s own caution is part of the record rather than something to be argued away. Ask which line of that table your proposed injection sits on. A physician who cannot answer has not read it either.

Frequently asked questions

What evidence level does ASIPP give intradiscal PRP?

Level III, Fair, with a moderate consensus-based clinical recommendation, in the 2025 update to its guidelines on regenerative therapies for chronic low back pain. Intradiscal bone marrow aspirate concentrate and epidural PRP carry the same grading; facet and sacroiliac indications are graded lower. Learn more: the full 2024 to 2026 guideline record.

Can PRP be injected into a herniated disc after a car accident?

It is one of the indications the 2025 ASIPP guideline addresses, at Level III, Fair with a moderate recommendation, and it applies to chronic low back pain after a thorough diagnostic evaluation rather than to the acute phase of a fresh injury. Sequencing is part of the recommendation. Learn more: what sits between conservative care and surgery.

Why does my doctor want a diagnostic block before injecting anything?

Because low back pain is a location, not a diagnosis. A block that reliably abolishes the pain and lets it return as the anesthetic wears off identifies the structure carrying the signal; a block that changes nothing has disproved an expensive assumption cheaply. Learn more: how two diagnostic blocks change a fusion conversation.

Is a sacroiliac PRP injection as well supported as a disc injection?

No. ASIPP grades sacroiliac joint PRP at Evidence Level IV, Limited, with a low consensus recommendation, compared with Level III, Fair and a moderate recommendation for intradiscal and epidural PRP. The grades are target-specific and do not transfer. Learn more: how the societies graded each indication.

Does an injection replace physical therapy?

No, and the guideline is explicit that these treatments should be used together with structured exercise, physical therapy and lifestyle management. The interventional procedure creates a window in which rehabilitation can work. Learn more: why the biological environment decides whether the window holds.

Where is Injury Experts located?

Injury Experts is at 4477 Woodson Rd, Suite 202, St. Louis, MO 63134, next to Lambert International Airport, serving the St. Louis region in Missouri and Illinois. Call (314) 887-5866 or text (314) 886-5902.

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP — Board Certified in Anesthesiology, Pain Medicine, Interventional Pain Management, Addiction Medicine, and Obesity Medicine.

This article is for general education and is not medical advice. It does not create a physician–patient relationship. Do not start, stop, or change any medication — including opioid medication — without consulting your physician.

The knee hits the dashboard. Six weeks later the MRI report comes back and somewhere in it are the words degenerative changes, and an adjuster with a highlighter has everything they need.

The argument writes itself: this knee was already arthritic, the collision merely revealed it, and the claim is worth a fraction of what was asked. It is a good argument against a patient who does not know how joints actually fail.

The injury does not reveal the arthritis. It starts it.

Post-traumatic osteoarthritis is its own diagnosis, and it is common. Roughly half of people who tear an anterior cruciate ligament develop osteoarthritis in that knee, and reconstruction does not reliably prevent it — reviews of the literature have not found convincing evidence that surgical reconstruction lowers the incidence compared with conservative management.

Read that in the direction time actually runs. A joint injured today carries a materially elevated risk of arthritis for decades, which makes a knee injury a question about the next thirty years, not about the next appointment. The defense wants a conversation about what your cartilage looked like last month. The medicine is a conversation about what it will look like in 2046. How exacerbation of a pre-existing condition is actually proven, and why the eggshell doctrine exists at all.

Where PRP sits on the grading scale

Knees are graded Kellgren-Lawrence 0 through 4, from no visible change to bone-on-bone. The 2024 ESSKA-ICRS consensus rated 216 scenarios crossing that grade with age, compartment, effusion and what had already been tried. Its conclusion: intra-articular PRP is appropriate in patients aged 80 or under with grade 0 to 3 arthritis, after conservative or injective treatment has failed. Not as a first move.

The companion ESSKA-ORBIT consensus put three statements at grade A, its highest tier: that the preclinical and clinical evidence supports PRP use in knee osteoarthritis; that effectiveness is shown in mild to moderate disease at grade 3 or below; and that PRP provides a longer-lasting effect than corticosteroid with a safer profile. The 2026 AAPM&R guidance statement added five evidence-based recommendations and eleven best practices on how to select patients and administer it responsibly.

What the head-to-head trials found

Against hyaluronic acid, a meta-analysis of 18 level-1 studies — 811 patients on PRP, 797 on hyaluronic acid — found mean WOMAC improvement of 44.7% against 12.6%. In the same analysis, leukocyte-poor preparations produced better subjective knee scores than leukocyte-rich ones, which is a finding about how the product is made rather than about what it is called.

Against corticosteroid, a 2024 network meta-analysis found PRP, bone marrow concentrate and hyaluronic acid all outperforming steroid on pain and function at a minimum of six months. And a 2025 meta-analysis of randomized trials found the improvement clinically significant, with the size of the effect influenced by the platelet concentration actually delivered.

That last point is not a footnote. It is why two clinics injecting “PRP” can produce two different results and both be telling the truth about what they used. What has to be recorded for the injection to be describable.

Grade 4, where the consensus stops and the decision becomes yours

The ESSKA-ICRS panel did not extend its appropriateness rating to grade 4 knees. Read the underlying numbers rather than the headline: across the whole exercise, 4.2% of scenarios were rated inappropriate and 56.9% uncertain, and grade 4 fell overwhelmingly into uncertain rather than into inappropriate. Uncertain is a statement about the evidence, not a prohibition.

The trial evidence at that grade exists and is worth stating precisely. A prospective, blinded, placebo-controlled study of serial PRP in Kellgren-Lawrence grade 4 knees — in patients unwilling to have joint replacement or carrying relative contraindications to it — reached clinically meaningful improvement in WOMAC and pain scores at three and six months, where saline did not. A four-year follow-up of bone marrow aspirate concentrate in 37 grade 3 and 4 knees reported improvement in 35, with no prosthesis implanted over the follow-up period. These are small studies. They are also the studies that exist for exactly the patient the consensus panel could not rate.

The position here is plain. At bone-on-bone, structure is not going to be restored, and joint replacement remains the definitive operation for the structure and for the person who wants it. But most grade 4 patients are not choosing between an injection and a replacement. They are choosing between an injection and another year of climbing analgesic doses. Time and a lower medication burden are legitimate clinical goals, and they are the goals worth naming out loud at that stage. What escalating medication does to the claim as well as the body.

The meniscus, where the answer is no

A torn meniscus is one of the most common findings after a twisting knee injury, and it is where the honest answer runs against the treatment. The 2019 ESSKA meniscus consensus reviewed biological enhancement — needling, PRP — and found no evidence that it improves healing of a repaired meniscus. What that consensus does say, emphatically, is that preservation beats removal: long-term outcomes after partial meniscectomy are worse than after repair, and many tears once called irreparable should be repaired.

So the meniscus conversation is about preserving tissue, not about injecting it. A page that claimed otherwise would be selling you something.

What has to be in the chart for a crash knee

The mechanism, in detail, recorded early. Baseline imaging read against the examination rather than in isolation, because a radiology report describing degenerative change says nothing about when that change started or whether it hurt last month. Functional measurement at intervals. And where a biologic is used, the indication mapped explicitly to the guideline scenario it belongs to, with the preparation characterized.

One more, and it is the one people skip: the metabolic background. Cartilage and synovium are not inert tissue waiting patiently; they behave differently in a systemically inflamed body, and the injectate is manufactured from that same body. Why the terrain is measured first.

Frequently asked questions

The insurance company says my knee arthritis is pre-existing. Is that the end of it?

No. Post-traumatic osteoarthritis is a recognized consequence of joint injury — roughly half of people who tear an ACL develop arthritis in that knee, and reconstruction has not been shown to reliably prevent it. The clinical question is what the injury started, not only what an image shows today. Learn more: proving exacerbation of a pre-existing condition.

What grade of knee arthritis is PRP appropriate for?

The 2024 ESSKA-ICRS consensus rated it appropriate in patients aged 80 or under with Kellgren-Lawrence grade 0 to 3 arthritis, after conservative or injective treatment has failed, and did not endorse it as a first-line treatment. Grade 4 was rated uncertain rather than inappropriate. Learn more: the full guideline record.

Is PRP better than a cortisone shot for an injured knee?

The ESSKA-ORBIT consensus rated it a grade A statement that PRP provides a longer effect than the short-lived effect of corticosteroid with a safer profile, and a 2024 network meta-analysis found PRP, bone marrow concentrate and hyaluronic acid all outperforming steroid at a minimum of six months. Individual results vary. Learn more: how targeted injections fit between conservative care and surgery.

Will PRP heal my torn meniscus?

The evidence does not support that claim. The 2019 ESSKA meniscus consensus found no evidence that biological enhancement improves healing of a repaired meniscus, and it emphasizes preserving meniscal tissue rather than removing it. Learn more: why preserving structure changes long-term outcomes.

Does bone-on-bone arthritis rule out an injection?

No. Structure will not be restored at that stage, and joint replacement remains the definitive operation for the structure. But a placebo-controlled trial in grade 4 knees found clinically meaningful improvement with serial PRP at three and six months where saline did not, and for many patients the real alternative is another year of rising medication doses. Learn more: what medication escalation costs, medically and legally.

How soon after a crash should a knee be evaluated?

Early, and in detail. The mechanism, the examination and baseline imaging recorded close to the event are what later separate an injury from an alleged pre-existing condition, and early findings also shape treatment. Learn more: what the first days after an injury predict.

Where is Injury Experts located?

Injury Experts is at 4477 Woodson Rd, Suite 202, St. Louis, MO 63134, next to Lambert International Airport, serving the St. Louis region in Missouri and Illinois. Call (314) 887-5866 or text (314) 886-5902.

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP — Board Certified in Anesthesiology, Pain Medicine, Interventional Pain Management, Addiction Medicine, and Obesity Medicine.

This article is for general education and is not medical advice. It does not create a physician–patient relationship. Do not start, stop, or change any medication — including opioid medication — without consulting your physician.

A denial letter and a demand letter are two different documents, written by two different people, answering two different questions. When they get read as if they answer the same question, the patient loses twice.

Two questions, routinely collapsed into one

The first question is medical: does this treatment work, for this problem, in this patient? It is answered by trials, meta-analyses and society consensus.

The second is financial: will a particular health plan pay for it? That is answered by a benefit committee deciding what to fund across an entire membership for a fixed premium pool. Plans decline to fund all sorts of things that work. The decision is about allocation.

Collapsing the second answer into the first is how “your plan will not pay for this” becomes “this does not work.” Nobody has to state the fallacy out loud for it to do its work on a claim file.

The society that wrote the guideline says the same thing about payment

ASIPP’s 2025 practice guideline on regenerative therapies for chronic low back pain runs to 119 pages, carries 19 recommendations at 100% panel agreement, and grades each lumbar indication under GRADE. Its precautions section instructs clinicians to inform patients that the costs of these treatments are mostly not covered by commercial insurance.

So the society and the insurer agree completely about payment, and disagree completely about evidence. That is the whole distinction, written by the specialty’s own guideline authors, and it is available to anyone arguing a claim file.

Prior authorization is not a promise of payment

This one costs patients real money and almost nobody says it plainly: insurers routinely reserve the right to decline a claim they authorized. Authorization is a statement about medical criteria at the time it was issued. Payment still turns on eligibility on the date of service, remaining benefits, and the plan’s own review after the claim is submitted.

Which means the useful question, asked before the service and answered in writing, is: if this authorized service is later denied, what am I responsible for? Ask it of the plan, not only of the clinic. An office can tell you what it was told. Only the plan can tell you what it will honor.

What this does to an injury claim

Adjusters do not evaluate a bill so much as score it, line by line, against a schedule that has no column for a treatment their software has not seen before. A biologic line item with no diagnosis in front of it and no outcome behind it is the easiest reduction in the file. How that scoring actually works.

What answers it is not indignation. It is the record: the diagnosis and the test that established it, the published guidance the indication maps onto, what was injected and how it was characterized, the imaging guidance used, and function measured at intervals afterward. That converts a disputed line item into documented care delivered inside a written standard. What that record looks like.

How treatment gets paid for while a case is open

Say the unpopular part first: the bill is for services rendered, and it is owed whether the case is won or lost. A medical lien is a timing mechanism. It changes when the bill is paid. It never changes whether it is owed.

Anyone who tells you otherwise is either confused or selling treatment on a contingency that does not exist, and patients who believe it accumulate care they think is free until the day the litigation disappoints them.

In Missouri, the statutory lien at RSMo 430.225 through 430.250 defines a health practitioner to include a physician and treats clinics on the same footing as hospitals. The lien attaches to the injured person’s claim against the party who caused the injury, and it has to be perfected by certified mail with return receipt requested, sent to the party alleged liable and any known insurer, before money changes hands. A letter of protection is a separate contractual layer, not a substitute — the statute supplies the right, the letter supplies the mechanics and the attorney’s undertaking.

Missouri work injuries are carved out of that statutory lien, which is why the first question in a work case is who authorized the care. If an adjuster referred you, it is handled as authorized care. If the carrier denied the care, the denial changes the footing and the route is usually through your attorney. Why the state line matters this much.

Illinois is not Missouri. A work injury there is handled much closer to a standard medical lien than Missouri’s carve-out permits. Ask which state the injury happened in early. It changes the paperwork, never the treatment.

What to do with all of this

Get the coverage answer in writing before the service, not after. Keep the denial letter — it is evidence of what the plan decided, not evidence about the medicine. Ask your treating physician which published guideline the recommended treatment maps onto, and put the answer in your own file. And tell your attorney early if a non-covered treatment is on the plan, because a line item nobody was warned about is the one that gets cut.

Frequently asked questions

If a treatment works, why will my insurance not pay for it?

Because coverage is a budgeting decision about what a plan funds across its whole membership, made against a fixed premium pool. Plans decline to fund things that work all the time. The medical question and the payment question have different decision-makers and different criteria. Learn more: the guideline record on orthobiologics.

Does prior authorization mean my insurer has agreed to pay?

No. Insurers routinely state that authorization is not a guarantee of payment; the claim still turns on eligibility on the date of service, remaining benefits and the plan’s post-submission review. Ask, in writing and before the service, what you owe if an authorized service is later denied. Learn more: how claims get scored rather than read.

If I lose my case, do I still owe the medical bill?

Yes. The bill is for services rendered. A lien affects when it is paid, not whether it is owed, and you remain responsible whether the case succeeds or fails. Anyone describing treatment as free if you lose is describing something else. Learn more: how Missouri and Illinois differ on injury claims.

What is a letter of protection?

A contractual undertaking, usually from your attorney, that the medical bill will be addressed out of any recovery. In Missouri it sits alongside the statutory lien rather than replacing it — the statute supplies the right and the letter supplies the mechanics. Learn more: how treatment decisions show up in the claim file.

Does a denial letter hurt my injury claim?

It should not, and it is worth understanding why. A plan’s non-coverage decision is about that plan’s benefits. The value of care in an injury claim is argued from medical necessity and reasonable value, which are established by the clinical record and the published standard of care. Learn more: what a court asks of medical opinion.

Where is Injury Experts located?

Injury Experts is at 4477 Woodson Rd, Suite 202, St. Louis, MO 63134, next to Lambert International Airport, serving the St. Louis region in Missouri and Illinois. Call (314) 887-5866 or text (314) 886-5902.

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP — Board Certified in Anesthesiology, Pain Medicine, Interventional Pain Management, Addiction Medicine, and Obesity Medicine.

This article is for general education and is not medical advice. It does not create a physician–patient relationship. Do not start, stop, or change any medication — including opioid medication — without consulting your physician.

Between 2024 and 2026, four professional bodies did something that quietly changes how an injury case involving orthobiologics gets argued. They wrote the standard down.

ESSKA and the International Cartilage Regeneration and Joint Preservation Society published a formal consensus on platelet-rich plasma for knee osteoarthritis. The American Academy of Orthopaedic Surgeons published a technology overview built on a systematic review. The American Academy of Physical Medicine and Rehabilitation issued a guidance statement in 2026. The American Society of Interventional Pain Physicians published a 119-page practice guideline on regenerative therapies for chronic low back pain, with 19 recommendations, every one at 100% agreement among the consensus panel.

None of that is advertising. It is a paper trail. A claim is made of paper trails.

What now exists, and how each document was built

The method matters more than the conclusion, because the method is what a defense expert has to attack.

• ESSKA-ICRS consensus, 2024. Built with the RAND/UCLA Appropriateness Method — 216 defined clinical scenarios rated by a panel, crossing age, grade of arthritis, compartment, effusion, and what had already been tried.
• ESSKA-ORBIT consensus, 2024. Twenty-eight question-and-statement sets on blood-derived products, each carrying a letter grade from A (high-level scientific support) down to D (expert opinion), then rated for agreement by a separate panel.
• AAOS Technology Overview, 2024. A systematic review that came back with 54 articles, 36 of them high quality, on PRP for knee osteoarthritis against every common comparator including saline, corticosteroid, hyaluronic acid, exercise, and bone marrow concentrate.
• AAPM&R guidance statement, 2026. A technical expert panel and a modified Delphi process, built on a structured literature review updated through June 2025, producing five evidence-based recommendations and eleven consensus-based best practices.
• ASIPP guidelines, 2025 update. Thirty-five authors, GRADE methodology, indication-by-indication evidence levels for the lumbar spine.
• Multispecialty chronic pain guidelines, 2024. Sixteen questions appraised against United States Preventive Services Task Force criteria, spanning tendinopathy, muscle, joint, disc, and neuropathic indications.

Professional societies do not convene panels, run Delphi rounds and publish appropriateness tables about treatments they consider unsettled curiosities. They do it when a treatment is in wide clinical use and the profession needs to say where it belongs and where it does not.

What the documents say about joints

The ESSKA-ORBIT panel issued three grade A statements — its highest evidentiary tier. There is sufficient preclinical and clinical evidence to support PRP use in knee osteoarthritis. Clinical evidence shows effectiveness in mild to moderate disease, Kellgren-Lawrence grade 3 or below. And PRP provides a longer effect than the short-lived effect of corticosteroid injection, with a safer profile — the statement that drew the strongest agreement of the entire document.

The ESSKA-ICRS panel went finer. Of its 216 scenarios, 38.9% were rated appropriate, 4.2% inappropriate, and 56.9% uncertain. The strongest consensus was for PRP after injective treatments had already failed. Appropriate, in that document, means a patient aged 80 or under, with grade 0 to 3 arthritis, who has already been through conservative care.

Underneath the consensus statements sit meta-analyses of randomized trials. Compared with hyaluronic acid across 18 level-1 studies, PRP produced a 44.7% mean improvement in total WOMAC score against 12.6% — and leukocyte-poor preparations outperformed leukocyte-rich ones. A 2024 network meta-analysis found PRP, bone marrow concentrate and hyaluronic acid all outperforming corticosteroid on pain and function at a minimum of six months. A 2025 meta-analysis found the improvement clinically significant, and dependent on how much platelet concentration was actually delivered.

What the documents say about the injured spine

ASIPP graded each lumbar indication separately, and the grades are not interchangeable:

• Intradiscal PRP — Evidence Level III, Fair. Consensus recommendation: Moderate.
• Intradiscal bone marrow aspirate concentrate — Level III, Fair. Moderate.
• Epidural PRP — Level III, Fair. Moderate.
• Facet joint PRP and mesenchymal stem cells — Level IV, Limited. Moderate.
• Sacroiliac joint PRP — Level IV, Limited. Low.

That is not a marketing table. It is a society telling its own members exactly how far the evidence reaches for each target, and where it thins out. The same guideline says regenerative medicine “remains in early stages of clinical validation” and asks for careful optimism. Both halves are true at once, and the honest version of this page carries both.

The sentence in these documents that nobody quotes

Every one of them sequences the treatment. ASIPP stipulates that regenerative therapy follows a thorough diagnostic evaluation and runs alongside structured exercise, physical therapy and lifestyle management. The ESSKA-ICRS appropriateness ratings are built on what has already been tried and failed. PRP as a first move, before anything has been diagnosed or attempted, is the one thing the knee consensus explicitly declines to endorse.

That is a rule about order, and it is the rule most often broken — by clinics that sell an injection as a product, and by claims that arrive with a biologic line item and no diagnostic work in front of it. An injection is not the treatment. It is what makes the treatment possible.

Where the record is thin, because the other side will find it

It is indication-specific, and so is every honest sentence about it.

ASIPP's own table is the clearest example: intradiscal PRP and bone marrow concentrate at Level III, Fair; epidural PRP at Level III, Fair; facet joint injection at Level IV, Limited; sacroiliac at Level IV, Limited. Four targets a few inches apart, and four different evidentiary tiers. A citation earned at one target does not travel to the next one, and a defense expert who knows that table will say so.

The 2019 ESSKA meniscus consensus is equally direct: it does not establish biological enhancement as a treatment that improves the healing of a repaired meniscus. That is a society declining to endorse an indication, and a claim that asserts otherwise is exposed.

And the reporting itself is uneven. A systematic review of 25 randomized trials in knee osteoarthritis found they reported, on average, 53.1% of the items on the orthopedic profession's own minimum reporting checklist. Not one hit 80%. The category reported worst was activation — a variable that changes what the injectate actually is.

None of that makes the knee and elbow evidence disappear. It means a treatment described only as “PRP” on a bill has not really been described at all. Why the characterization is the treatment.

Why a consensus statement matters to your claim

Two things get argued about medical care in an injury case: whether it was necessary, and whether its value was reasonable. Both are argued from the standard of care as the literature describes it.

Before these documents, an adjuster could treat a biologic injection as an outlier and value it accordingly. After them, a treatment given for a documented indication that maps onto a published scenario is not an outlier — it is care delivered inside a written standard, and the person disputing it has to argue with the society that wrote it, under oath, in front of someone whose job is to notice. What Daubert asks of that argument.

Coverage is a separate question with a separate answer. Most plans do not pay for these injections, and that is a budgeting decision about what a plan funds across its whole membership — not a finding about whether the treatment works. The difference between not covered and not proven.

How this is actually practiced here

The guidelines describe a sequence. So does the clinic.

Diagnosis comes first, and it is a real diagnosis: imaging read against the examination, electrodiagnostic testing where the question is nerve, and diagnostic blocks where the question is which structure carries the signal. A block that abolishes the pain and lets it return on schedule has proven something. A block that does nothing has disproved something cheaply, before anyone injected anything expensive into it. How a diagnostic block earns its place.

Then the terrain. These products are autologous — the injectate is made from the patient, so the patient’s biology is the raw material. Systemic inflammation, insulin resistance, poor sleep and nicotine are not lifestyle footnotes here; they are the manufacturing conditions. Why we measure the terrain before we inject.

Then delivery, under ultrasound or fluoroscopic guidance, with the preparation characterized and recorded. Then function measured at intervals, in numbers, so that improvement is a data series and not a memory. And alongside all of it, the unglamorous work — loading the tissue, sleeping, eating in a way that lowers the inflammatory background. Roughly half of what happens in this practice is behavioral, and it is the half that decides whether the other half holds.

What to ask before you agree to any biologic injection

1. What is the diagnosis, and what test established it?
2. Which published guideline or consensus scenario does my situation map onto, and where does it fall in that document?
3. What is being injected — platelet dose, leukocyte content, volume, whether it is activated?
4. Under what imaging is it being placed?
5. What measure will tell us at three months whether it worked, and what happens if it did not?
6. What is being done about the biology that will be there tomorrow?

A clinic that can answer those six is practicing inside a standard. A clinic that cannot is selling a syringe, and the record it produces will not survive contact with a defense expert.

Frequently asked questions

Is PRP still considered an unsettled treatment?

Not by the bodies that write the standards. Between 2024 and 2026, ESSKA and ICRS, the AAOS, AAPM&R and ASIPP all published consensus documents or guidance with graded recommendations, and those grades are indication-specific rather than blanket. Coverage is a separate matter from evidence. Learn more: Not covered is a budget decision, not a verdict on the evidence.

What does Level III, Fair, with a moderate recommendation actually mean?

It is ASIPP’s grading for intradiscal and epidural PRP in chronic low back pain: the supporting studies are mostly observational or lower-tier controlled evidence, appraised with GRADE, and the panel reached moderate consensus that the treatment has a role in appropriately selected patients. It is a measured statement, not a promise. Learn more: What a pain society actually says about injecting an injured disc.

Does a guideline make my treatment automatically defensible in a claim?

No. It makes the argument a medical one instead of a rhetorical one. What carries a claim is the record: a diagnosis established by a test, an indication that maps to a published scenario, the product characterized, the guidance modality named, and function measured over time. Learn more: Write the note like a defense expert will read it.

Is PRP appropriate for every painful joint after a crash?

No, and the honest reading of the evidence is that it is indication-specific. The knee and lateral elbow evidence is comparatively strong; randomized-trial meta-analyses in Achilles tendinopathy and rotator cuff disorders did not show clinical benefit. A citation earned in one joint does not transfer to another. Learn more: What the knee guidelines say, grade by grade.

Why does the clinic test metabolic markers before injecting?

Because the injectate is made from you. Platelet products act on the tissue environment they land in, and a persistently inflamed, insulin-resistant environment is working against the repair you are paying for. Learn more: Why the terrain comes before the biologic.

Will my health plan pay for this?

Usually not. Most commercial plans and Medicare do not cover orthobiologic injections, and the ASIPP guideline instructs clinicians to tell patients so before treatment. Non-coverage is a decision about what a plan funds, and prior authorization for anything is not a guarantee of payment. Learn more: How coverage and evidence get confused.

Where is Injury Experts located?

Injury Experts is at 4477 Woodson Rd, Suite 202, St. Louis, MO 63134, next to Lambert International Airport, serving the St. Louis region in Missouri and Illinois. Call (314) 887-5866 or text (314) 886-5902.

What a Pain Society Actually Says About Injecting an Injured Disc explains what that looks like.

Key takeaways

• Four societies published graded guidance on orthobiologics between 2024 and 2026; the grades are indication-specific and do not transfer between joints.
• Every one of those documents sequences the treatment: diagnosis first, conservative care first, biologic after — and alongside exercise, rehabilitation and lifestyle management.
• The evidence is negative in some indications, including Achilles tendinopathy and rotator cuff disorders, and that belongs in an honest account.
• Most plans do not pay for these injections. Non-coverage is a budgeting decision, not a finding about whether the treatment works.
• In a claim, what carries the treatment is the record: indication mapped to a published scenario, product characterized, placement guided, function measured.

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP — Board Certified in Anesthesiology, Pain Medicine, Interventional Pain Management, Addiction Medicine, and Obesity Medicine.

This article is for general education and is not medical advice. It does not create a physician–patient relationship. Do not start, stop, or change any medication — including opioid medication — without consulting your physician.

Months after a rear-end collision, the neck pain has not settled. Imaging shows degenerative change, physical therapy has plateaued, and the next appointment on the calendar is a surgical consultation. That is the point at which a great many injured people agree to a cervical fusion — not because fusion was proven to be the answer, but because it was the only option anyone put in front of them.

There is a step that belongs before that decision, and it is diagnostic rather than surgical.

Where post-collision neck pain usually comes from

The cervical facet joints are the small paired joints at the back of each vertebral level. They guide motion and they take load, and in a whiplash mechanism — rapid extension followed by flexion — they are among the structures most reliably injured.

Published prevalence work using controlled diagnostic blocks has put cervical facet joint involvement at roughly half of chronic neck pain after a collision, with individual studies ranging higher or lower depending on the population and the diagnostic threshold used. That matters because facet-mediated pain does not appear on an MRI as a discrete lesion. The imaging looks like ordinary degeneration, which is precisely why it is so often attributed to age rather than to the crash.

The diagnostic step that settles the question

The medial branch nerves are small sensory nerves that carry pain signals from each facet joint. They can be anesthetized individually.

A medial branch block places a small volume of local anesthetic at those nerves. If the pain that has resisted months of conservative care goes quiet for the duration of the anesthetic, the facet joint is the pain generator. If nothing changes, it is not — and a great deal of unnecessary treatment has just been avoided.

The convention in interventional practice is to perform two blocks rather than one, because a single positive block carries a meaningful false-positive rate. Two concordant responses, each producing a high degree of relief, is the standard that supports proceeding.

What radiofrequency ablation actually does

If the blocks confirm the facet joints, radiofrequency ablation treats them. A probe is positioned at the same medial branch nerves and heated, interrupting their ability to transmit pain signals from that joint.

It is worth being precise about what this is and is not:

• It is an outpatient procedure, performed with local anesthetic and light sedation rather than general anesthesia.
• It does not fuse, remove, or replace any structure. Nothing is permanently altered in the spine’s mechanics.
• The nerves regenerate. Relief is durable but finite — reported ranges commonly fall between several months and roughly two years, after which the procedure can be repeated.
• If it does not work, every surgical option remains open. Nothing has been foreclosed.

Reported success rates in the published literature typically describe around half to two-thirds of appropriately selected patients achieving at least fifty percent pain relief. Those figures depend heavily on selection — which is the entire argument for doing the diagnostic blocks first. Individual results vary.

The order of operations is the whole point

Fusion is a reasonable operation for the right problem. It is a poor operation for facet-mediated pain, because it does not address the pain generator and it permanently changes how load transfers through the adjacent levels.

The sequencing argument is straightforward: the less invasive, reversible, diagnostically-confirmed option comes first. Doing the irreversible one first, when the reversible one might have worked, is difficult to justify clinically — and, in a claim, difficult to justify economically.

The cost differential between an ablation and a cervical fusion is substantial, commonly an order of magnitude or more once facility, implant, anesthesia and rehabilitation are counted. We are not going to publish a price here, because the number depends on level count, facility and payer. But the direction is not in dispute, and it is one of the reasons this sequence matters in a personal injury context.

Why this matters for causation

Insurers routinely argue that chronic neck pain after a collision is degenerative — that the imaging shows wear the patient already had, and the crash merely coincided with it.

A diagnostic medial branch block is one of the few tools that answers that argument with something other than the patient’s own report. It is an objective, reproducible test that localizes the pain to a specific joint at a specific level. A documented, concordant response to two blocks is materially harder to dismiss than a pain diary.

That is a documentation question as much as a medical one. We wrote about the broader version of that problem in proving causation when a pre-existing condition is in play, and about the scoring systems adjusters actually use in how insurance adjusters devalue injury claims.

The rule that a diagnosis has to precede the needle is not local practice. It is written into the 2025 ASIPP guideline on regenerative therapies for the lumbar spine. What that guideline requires, target by target.

Frequently asked questions

How do I know whether my neck pain is coming from the facet joints?

You cannot know from imaging alone, which is the central difficulty. Facet-mediated pain typically worsens with extension and rotation — arching and turning the head — and is confirmed by a diagnostic medial branch block rather than by MRI. See what facet joint pain actually feels like for how this is worked up.

Is radiofrequency ablation permanent?

No. The treated nerves regenerate over time and pain can return, at which point the procedure can be repeated. That is a feature rather than a defect — nothing is permanently altered, and surgical options remain available. Individual results vary.

This is set out in You Have Been Offered Two Bad Options.

If ablation fails, have I lost the chance to have surgery?

No. Ablation forecloses nothing. This is the main reason to sequence it first. Read more on the two options injured patients are usually offered.

My insurer says the crash did not cause this. Does a block help?

It can. A concordant response to two diagnostic blocks localizes the pain to a specific joint and produces objective documentation rather than subjective report. See proving causation and exacerbation.

Where do I go for this evaluation?

Injury Experts, 4477 Woodson Rd, Suite 202, St. Louis, MO 63134, serving the St. Louis region across Missouri and Illinois. Call (314) 887-5866 or text (314) 886-5902. If your case involves a formal examination by the other side, read what an IME actually is first.

Key takeaways

• Roughly half of chronic post-collision neck pain is facet-mediated, and imaging will not show it.
• Two diagnostic medial branch blocks — not one — establish whether the facet joints are the pain generator.
• Radiofrequency ablation is outpatient, reversible, and forecloses no surgical option.
• Relief is durable but finite; the procedure can be repeated. Individual results vary.
• The same blocks that guide treatment also produce objective causation evidence.

Medically reviewed by Gurpreet Singh Padda, MD, MBA, MHP — Board Certified in Anesthesiology, Pain Medicine, Interventional Pain Management, Addiction Medicine, and Obesity Medicine. Last reviewed August 2026.

This article is educational and is not a substitute for evaluation, diagnosis, or treatment by a physician. Individual results vary. Do not start, stop, or change any medication without consulting your physician. It is not legal advice.

If you were hurt in the St. Louis region, one of the largest variables in what happens next is not your injury. It is which side of the Mississippi you were standing on.

Missouri and Illinois answer three basic questions differently: who chooses your doctor, whether you can recover at all, and how much your own share of fault costs you. Two people with identical injuries in the same week, two miles apart, can end up in very different positions.

If you were driving uninsured in Missouri

This is the one that surprises people most, and it is worth knowing before you assume you have no claim — or that you have a full one.

Under RSMo 303.390, an uninsured driver is barred from recovering non-economic damages. That is pain, suffering, and loss of the life you had. The bar applies even when the collision was not your fault.

Two things matter enormously here, and both are routinely misstated:

It bars non-economic damages, not everything. Economic damages — medical bills, lost wages — are not addressed by that section. Anyone who tells you an uninsured driver “cannot get compensation” has overstated the statute.

There are exceptions, and the statute has been contested. The section does not apply where the collision was caused by a driver under the influence, or one convicted of involuntary manslaughter. Missouri courts have seen constitutional challenges to the provision, and the Missouri Supreme Court declined to resolve the question in a 2023 case because the argument had not been preserved for review. It remains on the books.

What this means practically: if you were uninsured, the economic side of your claim still has to be documented properly, and the documentation carries more weight than usual — because the subjective half of the claim may not be available to you.

If you were hurt at work

Here the two states diverge in a way that directly changes your medical care.

In Missouri, under RSMo 287.140, the employer — in practice the employer’s insurer — directs your treatment and selects the treating physician. You may see a physician of your own choosing, but at your own expense.

In Illinois, under 820 ILCS 305/8(a), the injured worker may select up to two medical providers, and referrals made by those providers are covered.

That is not a technicality. It determines who decides which specialist you see, when imaging gets ordered, and when you are declared to have reached maximum medical improvement. Same injury, same week, two miles apart — two different medical realities.

If you were partly at fault

Both states reduce an award by the injured person’s share of fault. Only one of them lets that share end the claim.

Missouri applies pure comparative fault. Under Gustafson v. Benda (1983), Missouri abandoned contributory negligence for the Uniform Comparative Fault Act approach. A plaintiff found 99% at fault can still recover, with the award reduced accordingly.

Illinois applies a modified rule with a 51% bar. Under 735 ILCS 5/2-1116, a plaintiff whose share of fault reaches 51% recovers nothing at all.

The Illinois rule creates a cliff rather than a slope. At 50% fault an award is halved; at 51% it is gone. That single percentage point is often the whole argument in a contested liability case — and what determines which side of it you land on is usually the quality of the contemporaneous record, not the eloquence of the closing.

What Missouri law says about how insurers must behave

Missouri also has a statute on claims conduct: RSMo 375.1000 through 375.1018, which defines improper claims practices. It reaches misrepresenting facts, failing to investigate, refusing to settle without a reasonable basis, and unreasonable delay.

One detail is worth knowing: the statute is written to reach claimants and insureds — not only the person who bought the policy. An injured third party is inside that language.

Be precise about what that does and does not mean. The act is enforced through the Missouri Department of Commerce and Insurance. Whether and how it supports a particular argument in a specific claim is a question for your attorney, not for a physician and not for a web page.

Why this lands on the medical record

Every one of the rules above is decided on documentation.

Whether an uninsured Missouri driver recovers their economic damages depends on how well those damages are evidenced. Whether a Missouri work-injury patient gets the imaging that shows the problem depends on what the treating physician — chosen by the insurer — actually orders and writes down. Whether an Illinois plaintiff sits at 49% or 51% often turns on dated, specific findings recorded close to the event.

This is the practical reason we treat intake as the most consequential appointment rather than a formality. How you were hurt, and where, determines what your medical record has to prove. How the record is scored once the claim is filed

Frequently asked questions

Can an uninsured driver recover anything in Missouri?

Who chooses my doctor in a workers’ compensation claim?

What happens if I was partly at fault?

Does Missouri law require insurers to deal fairly with an injured third party?

Where is Injury Experts located?

Key takeaways

• RSMo 303.390 bars non-economic damages for an uninsured Missouri driver — not economic damages such as medical bills and lost wages — and the bar applies even when the collision was not your fault.
• Missouri employers direct work-injury care and select the treating physician (RSMo 287.140); Illinois workers may select up to two providers, and referrals from them are covered (820 ILCS 305/8(a)).
• Missouri is pure comparative fault; Illinois bars recovery at 51% (735 ILCS 5/2-1116).
• RSMo 375.1000–375.1018 reaches claimants, not only insureds, and is enforced through the Missouri Department of Commerce and Insurance.
• Every one of these rules is decided on the contemporaneous medical record.

Sources

Statutes and case law change. This page is general information about Missouri and Illinois law, not legal advice, and it is not a substitute for advice from counsel about your own matter.

1. RSMo 303.390 — bars recovery of non-economic damages by an uninsured motorist; exceptions for intoxicated drivers and involuntary manslaughter convictions. Constitutional challenges have been litigated in Missouri; the Missouri Supreme Court declined to reach the question in Bridegan v. Turntine (2023) on preservation grounds.
2. RSMo 287.140 — employer or insurer selects the treating physician; the employee may choose their own at their own expense.
3. 820 ILCS 305/8(a) — injured worker may select two medical providers; referrals from them are covered.
4. Gustafson v. Benda, 661 S.W.2d 11 (Mo. banc 1983) — Missouri adopts pure comparative fault.
5. 735 ILCS 5/2-1116 — Illinois modified comparative negligence, 51% bar.
6. RSMo 375.1000–375.1018 — improper claims practices; § 375.1007 enumerates the prohibited acts and refers to “claimants and insureds.” Enforcement runs through the Missouri Department of Commerce and Insurance.

There is a version of injury care where the patient is managed on escalating narcotics for a year and a half. By the time anyone reaches a deposition, the other side is no longer arguing about the collision. They are reading out a medication list.

That shift is not an accident, and it is not really about the drugs. It is about what a long opioid record lets someone argue: that the pain was managed rather than treated, that function never returned because of the treatment, and that the person in the chair is not a reliable narrator of their own body.

Why medication-only management fails the patient first

Set the claim aside for a moment, because the clinical argument comes first and it stands on its own.

An opioid does not treat an injury. It changes the perception of the signal the injury is generating. That is genuinely useful in the short term and after surgery. Sustained for months, it stops being a bridge and becomes the destination — while the thing generating the signal goes unaddressed.

Worse, the underlying terrain often continues to deteriorate. Inflammation, poor sleep and lost movement are not side issues in a stalled recovery; they are the mechanism of it, and none of them are touched by a prescription. Why the tissue is not healing

Do not start, stop, or change any medication without consulting your physician. Abrupt discontinuation of an opioid is dangerous, and nothing here is a reason to do it on your own.

What we do instead

Our approach is interventional first. Find the specific structure generating the pain, treat that structure, and document what happened when it was treated.

A targeted diagnostic block is the clearest example. When a precisely placed anesthetic reliably abolishes a specific pain, and the pain returns as the block wears off, two things have been accomplished at once: the patient has relief, and the pain circuit has been demonstrated to exist and localized. That is a physiological finding rather than a report of symptoms.

We do not run medication-only management. Where opioids are used, they are a component of a plan with an exit, not the plan itself.

The numbers from our own practice

These are our practice-reported figures, not results from a clinical trial:

• 21% of patients under active interventional treatment are completely off opioid pain medication within 90 days.
• 34% are completely off opioid pain medication within one year.
• Across our established patients, fewer than 1% remain above 90 morphine milligram equivalents per day, and most who cannot come off entirely are held below 30 MME.

Practice-reported figures from our own patient population, not trial outcomes. Individual results vary.

The reason to state them at all is that they describe a direction of travel. A patient whose function is improving and whose medication burden is falling is in a different clinical position — and a different evidentiary position — than one whose dose has climbed every quarter for a year.

Why this matters to the case

A patient who is getting better is a better witness than a patient who is getting comfortable.

That is not a slogan about character. It is about what the record shows. Improving function under targeted treatment produces dated, objective evidence of an injury that responded to appropriate care. A long escalating opioid record produces something else entirely: a timeline that invites argument about dependence, motivation and credibility, and that shifts attention away from the injury and onto the patient.

The same principle runs through the rest of injury documentation. Systems that value claims discount the subjective and reward the documented — so the answer to a disputed injury is density of objective findings, not volume of assertion. How objective findings answer the malingering label

What this is not

This practice is not a source of continuing opioid prescriptions. Patients are frequently referred here to reduce an opioid burden, and that is the direction the work runs. If what is needed is continuation of an existing prescription, this is not the right referral.

It is also not a claim that opioids are never appropriate. They have a real place — short-term, post-operative, and in specific cancer and palliative contexts under co-management. The argument here is narrower: medication-only management of a traumatic injury tends to serve neither the patient’s recovery nor the accuracy of the record.

Frequently asked questions

Will taking prescribed pain medication hurt my injury claim?

What is an interventional-first approach?

What does a diagnostic block prove?

Do you prescribe opioids?

Where is Injury Experts located?

Key takeaways

• Opioids alter the perception of a signal; they do not treat the structure generating it.
• Medication-only management leaves the underlying terrain — inflammation, poor sleep and lost movement — untouched, and that terrain is the mechanism of a stalled recovery.
• Interventional-first care produces objective, dated findings as a by-product of treating the structure generating the pain.
• Practice-reported: 21% fully off opioid pain medication within 90 days, 34% within one year.
• Never start, stop, or change a medication without consulting your physician.

Verified sources

1. Opioid outcome figures (21% within 90 days; 34% within one year; fewer than 1% of established patients above 90 MME; most maintained below 30 MME) — practice-reported from the Padda Institute patient population. Not trial outcomes, and individual results vary. The tiers are distinct: new patients frequently arrive above 90 MME, while fewer than 1% of established patients remain there. These figures were published publicly on International Overdose Awareness Day, August 31, 2026, and carried by AP News; the original release is here.
2. Diagnostic block as objective demonstration of a pain circuit — standard interventional pain practice; described here mechanistically rather than as a cited efficacy claim.